STOCK TITAN

Avanos Medical (AVNS) Stock News

AVNS NYSE

Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.

Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.

Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.

Rhea-AI Summary

Avanos Medical, Inc. (NYSE: AVNS) announced the appointment of Dr. Lisa Egbuonu-Davis as an independent member of its board of directors, effective March 6, 2023. Egbuonu-Davis, who previously held senior roles at Sanofi and co-founded ROI Squared, brings extensive experience in healthcare strategy and operations. Avanos board chair Gary Blackford expressed optimism about her contributions to the company’s mission of providing innovative healthcare solutions, particularly in reducing opioid use. With Egbuonu-Davis's addition, the board now has six directors, including five independents and two women.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
management
-
Rhea-AI Summary

Avanos Medical, Inc. (NYSE: AVNS) reported strong fourth quarter and full-year 2022 results, with net sales of $217 million for Q4, up 12% year-over-year, and full-year net sales reaching $820 million, a 10% increase. Diluted EPS for Q4 was $0.36, compared to $0.24 a year earlier, while adjusted diluted EPS rose to $0.60 from $0.50. The company reported a free cash flow of $29 million in Q4 and $72 million for the year. Avanos is implementing a three-year transformation plan, targeting cost savings of $45-$55 million, amid ongoing developments in its product portfolio and operational efficiencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary

Avanos Medical, Inc. (NYSE: AVNS) will host a conference call on February 21 at 9 a.m. ET to discuss its financial results and business highlights for the fourth quarter and full year 2022. A news release detailing the results will be issued before market opens that day. The call will feature CEO Joe Woody and CFO Michael Greiner. Participants can join via phone or through a live webcast available on the company's investor website. A replay will be available beginning February 21 at noon ET for one week.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences earnings
Rhea-AI Summary

Avanos Medical (NYSE: AVNS) has announced the appointment of Michael Greiner as Chief Transformation Officer, alongside his role as CFO, and Kerr Holbrook as Senior Vice President and Chief Commercial Officer. This leadership shift aims to enhance the company's strategic focus and optimize financial performance over the next three years. The transformation plan centers on four priorities: optimizing the commercial organization, transforming the product portfolio, implementing cost management initiatives, and disciplined capital deployment. The new structure aims to accelerate sales and improve market impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary

Avanos Medical (NYSE: AVNS) will be represented by CEO Joe Woody at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at approximately 4:30 p.m., PST. A webcast of the presentation will be accessible on the Investors section of the Avanos Medical website, and it will be archived for future viewing. Avanos is dedicated to advancing healthcare needs by providing innovative medical device solutions aimed at enhancing patients' quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences
-
Rhea-AI Summary

Avanos Medical has appointed Sudhakar Varshney as the new senior vice president of global supply chain & procurement, effective immediately. Varshney brings over 20 years of leadership experience in various sectors including medical devices and automotive, having previously served at Antylia Scientific and other notable companies. His role entails leading a team of over 2,500 employees to enhance the company’s supply chain operations amidst ongoing global challenges. CEO Joe Woody expressed confidence in Varshney's ability to drive essential process improvements for the company’s growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
management
Rhea-AI Summary

Avanos Medical, based in Alpharetta, Georgia, will present at the Stifel 2022 Healthcare Conference on November 15 at 3:35 p.m. ET. CEO Joe Woody and CFO Michael Greiner will lead the presentation. The conference will be accessible via a webcast on the Avanos Medical website's investors section, with an archive for later viewing. Avanos Medical focuses on developing innovative medical devices aimed at improving patient quality of life and reducing opioid use. The company operates in over 90 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
conferences
-
Rhea-AI Summary

Avanos Medical reported third quarter 2022 financial results with net sales of $202 million, marking a 10% increase year-over-year. Gross margin improved to 54%, up from 49% in the prior year. The company achieved a net income of $16 million compared to a $35 million loss last year, and adjusted earnings per share rose to $0.38. Free cash flow reached $23 million. The company reaffirms its 2022 guidance, projecting net sales between $815 million and $835 million despite ongoing supply chain challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
-
Rhea-AI Summary

Avanos Medical (NYSE: AVNS) will host a conference call on November 2, 2022, at 9 a.m. ET to discuss its third-quarter financial results and business highlights. A news release will precede the call, detailing the company's performance. The call will be led by CEO Joe Woody and CFO Michael Greiner. Interested parties can join by dialing 877-240-5772 within the U.S. The replay will be available following the event for one week. Avanos focuses on providing innovative medical solutions to improve patient recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
conferences earnings
Rhea-AI Summary

Avanos Medical (NYSE: AVNS) announced that CEO Joe Woody and CFO Michael Greiner will participate in a fireside chat during the Morgan Stanley Global Healthcare Conference on September 14, 2022, at around 1:30 p.m. ET. A webcast of their presentation will be available on the Investors section of Avanos Medical's website and will be archived there for future reference. Avanos Medical focuses on delivering innovative medical device solutions that enhance patients' quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences

FAQ

What is the current stock price of Avanos Medical (AVNS)?

The current stock price of Avanos Medical (AVNS) is $24.88 as of June 30, 2026.

What is the market cap of Avanos Medical (AVNS)?

The market cap of Avanos Medical (AVNS) is approximately 1.2B.